Humacyte, Inc. (HUMA) Reports In-Line Q4 EPS

Humacyte, Inc. (NASDAQ: HUMA) reported Q4 EPS of ($0.24), in-line with the analyst estimate of ($0.24).

For earnings history and earnings-related data on Humacyte, Inc. (HUMA) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Adobe beats Q3 targets, but soft Q4 sales guidance triggers dip
• FDA extends Symvess shelf life from 18 to 36 months